Cargando…

In vitro and in vivo activity of melflufen (J1)in lymphoma

BACKGROUND: Melphalan has been used in the treatment of various hematologic malignancies for almost 60 years. Today it is part of standard therapy for multiple myeloma and also as part of myeloablative regimens in association with autologous allogenic stem cell transplantation. Melflufen (melphalan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delforoush, Maryam, Strese, Sara, Wickström, Malin, Larsson, Rolf, Enblad, Gunilla, Gullbo, Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820867/ https://www.ncbi.nlm.nih.gov/pubmed/27044263 http://dx.doi.org/10.1186/s12885-016-2299-9

Ejemplares similares

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
por: Karlsson, Henning, et al.
Publicado: (2017)

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
por: Fryknäs, Mårten, et al.
Publicado: (2013)

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia
por: Hallböök, Helene, et al.
Publicado: (2011)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information
por: Lagerlund, Olof, et al.
Publicado: (2020)

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
por: Schepsky, Alexander, et al.
Publicado: (2020)

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
por: Miettinen, Juho, et al.
Publicado: (2023)

Hodgkin lymphoma – a survey of children and adolescents treated in Sweden 1985–2009
por: Englund, Annika, et al.
Publicado: (2015)

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index
por: Hu, Kefei, et al.
Publicado: (2010)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
por: Flanagan, Ken, et al.
Publicado: (2022)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
por: Gebraad, Arjen, et al.
Publicado: (2022)

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
por: Karlsson, Henning, et al.
Publicado: (2019)

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
por: Larocca, Alessandra, et al.
Publicado: (2021)

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
por: Gholiha, Alex Reza, et al.
Publicado: (2021)

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
por: Mörth, Charlott, et al.
Publicado: (2018)

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
por: Bringhen, Sara, et al.
Publicado: (2021)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
por: Hollander, Peter, et al.
Publicado: (2018)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
por: Lövborg, Henrik, et al.
Publicado: (2009)

Prognostic impact of abdominal lymph node involvement in diffuse large B‐cell lymphoma
por: Abdulla, Maysaa, et al.
Publicado: (2019)

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma
por: Mattsson Ulfstedt, Johan, et al.
Publicado: (2021)

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021)

P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022)

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors?
por: Andersson, Anne, et al.
Publicado: (2021)

Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma—Possible Estrogen Effects
por: Huang, Dan, et al.
Publicado: (2023)

5‐HT (2B) receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo
por: Löfdahl, Anna, et al.
Publicado: (2016)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
por: Mofers, Arjan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3nlsn0u60c8p0o3fssll9nns2i